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ABSTRACT
Objective: The main objective of the SCOPE study was to
estimate the total direct medical costs of patients with
treated chronic obstructive pulmonary disease (COPD) in
France according to severity stages.
Methods: Total medical resources consumption of a sam-
ple of COPD patients was collected over a 12-month
period through a national physician survey (including
both general practitioners and lung specialists). This
survey was completed for 255 patients. Data were then
extrapolated to all patients with diagnosed and treated
COPD in France. Average total medical resources con-
sumption of a COPD patient per year was €4366. Among
this cost 41% was directly related to COPD follow-up,
25% to COPD-related complications (mainly exacerba-
tions), and 34% to other diseases. More than one-third of
the total direct COPD cost was related to hospitalizations
and 31% to drug consumption. COPD-related costs
increased markedly with severity based on FEV1 (but data
suggested the existence of a threshold effect). SCOPE data
did not show any evidence of a signiﬁcant relationship
between direct medical cost and patient age, sex, addic-
tion to tobacco, or duration of COPD. The total medical
consumption of COPD patients in France was €3.5 billion
and accounted for 3.5% of the total medical expenditures
(prevalence of COPD was estimated 1.3% in the general
population).
Results: The SCOPE study revealed the high level of med-
ical resources consumption of patients with COPD.
Conclusions: The burden of COPD itself and its com-
plications appeared to be of considerable magnitude in
France especially for severe COPD.
Keywords: COPD, costs, France, severity staging.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
major cause of chronic morbidity and mortality
throughout the world [1] and further increase in its
prevalence and mortality can be predicted in the
coming decades [2] owing to a better diagnosis and
to the aging of the population [3]. Current deﬁni-
tion of COPD is a disease state characterized by air-
ﬂow limitation that is not fully reversible with
bronchodilators, features that do not change mark-
edly over several months. The airﬂow limitation is
usually both progressive and associated with an
abnormal inﬂammatory response of the lungs to
noxious particles or gases, the most common of
which worldwide is tobacco smoke [4]. A diagnosis
of COPD should be considered in any patient who
has symptoms of cough, sputum, or dyspnea and/or
a history of exposure to risk factors for the disease.
The diagnosis is conﬁrmed by spirometry. Follow-
ing GOLD recommendations, the presence of a
postbronchodilator FEV1 (forced expiratory volume
in 1 sec) <80% of the predicted value in combina-
tion with an FEV1/FVC (forced vital capacity)
<70% conﬁrms the presence of airﬂow limitation
that is not fully reversible [4]. Nevertheless, bron-
chiectasis, cystic ﬁbrosis, asthma, or other obstruc-
tive diseases, sometimes associated with a poorly
reversible airﬂow limitation, are not considered as
COPD.
COPD may lead to various complications such as
respiratory failure, right heart failure or cor pulmo-
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nale, polyglobulia, and late in the course of the
disease, pulmonary hypertension [5]. The course
of COPD is complicated by acute exacerbations
that occur with increasing frequency as disease
progresses. COPD is also associated with extrapul-
monary affects. The prevalence of coronary arterial
diseases is signiﬁcantly higher among COPD pa-
tients compared with individuals of the same age
and sex (22% vs. 14.5%). This is also true for car-
diac failure (13.5% vs. 2.5%) or neurologic disease
(14% vs. 3.5%) [6].
COPD results in an economic and social burden,
which appears to be both substantial and increasing
[1]. Limited quantitative information concerning
the economic and social burden of COPD have been
published.
Available studies concern the United States and
some European countries. In France, referenced
studies are only related to speciﬁc aspects of the dis-
ease, that is, the cost of oxygen therapy per year,
evaluated at €10,000 in 1996 for the most severe
cases [7] or the cost of an acute exacerbation
episode, approximately US$5000 on average [8].
Owing to the difﬁculty of identifying patients with
a validated diagnosis of COPD and the lack of
medical data in the claims from the French
National Health Insurance system, there are cur-
rently no possibilities of using any existing database
to estimate the costs of COPD and this important
question cannot be addressed without a speciﬁc
survey.
In this context, the SCOPE study was designed
to describe the medical resource used and costs
incurred by individuals with COPD in 2001 accord-
ing to disease severity.
Methods
The SCOPE study was an observational retrospec-
tive and prospective bottom-up cost-of-illness study,
based on a representative sample of patients pre-
senting with COPD. Investigators were general
practitioners (GPs) or lung specialists. The sampling
frame was constituted of a representative panel of
1000 GPs (THALES) widely used for medical stud-
ies in France [9] and a national list of ofﬁce-based
lung specialists in metropolitan France.
For the purposes of this study, COPD was
pragmatically deﬁned on the basis of the following
criteria:
• Patients over 45 years of age;
• With   a   tobacco   consumption   over   15
pack-years;
• With a chronic bronchitis deﬁned by the presence
of cough and sputum production or dyspnea for
at least 3 months in each of 2 consecutive years;
• Without asthma history at childhood; and
• With an airﬂow limitation FEV1/FVC <80%.
In France, spirometry is not systematically pro-
posed to all potential COPD patients followed by
GPs. To minimize bias related to change of practice
affecting our cost estimates, we did not require a
spirometry examination at inclusion. Instead, inves-
tigators were asked to enroll all suspected COPD
patients based on the following criteria: patients
over 45 years old, with a smoking history over 15
pack-years, a history of cough and sputum produc-
tion or dyspnea for at least 3 months in each of 2
consecutive years and a peak-ﬂow value of <80%
predicted.
When the patients had no spirometry test before
the recruitment or during the study follow-up, this
examination was systematically performed at the
end of the study period. When COPD was not con-
ﬁrmed with regard to the above criteria, patients
were excluded.
To minimize selection bias, patients were
enrolled consecutively during a 4-month period. At
enrollment visit, questionnaires were used to collect
data on consumption of medical resources retro-
spectively over the prior 3 months. Patients were
then followed and questionnaires were prospec-
tively completed at each visit required during a 9-
month (±1 month) period. The study was designed
to minimize any recall bias and to collect as exhaus-
tively as possible data on health-care consumption
of validated COPD patients for 1 year. At ﬁrst visit,
demographic data, medical history of patients, phy-
sician and paramedics’ visits, treatment, diagnosis
and lab tests, hospitalizations, oxygen therapy,
rehabilitation, and absence from work were col-
lected during the last 3 months. Similar data were
then collected at each consecutive visit during the
prospective follow-up period. Medical events,
occurrences of symptoms, and results of respiratory
tests were also recorded.
Medical resource consumptions were categorized
by investigators as usual COPD follow-up, COPD
complications, exacerbations, or other comorbidi-
ties not related with COPD. Costing was carried out
using a societal perspective including opportunity
costs without discounting. Unit costs data were
extracted from ofﬁcial tariffs for ambulatory care
and DRG national costs estimates for hospitaliza-
tion. All costs were expressed in Euros for year
2001 (1 US$ = 0.85 Euro).
Detournay et al.170
COPD patients were classiﬁed using the COPD
staging system recommended by the SPLF (French
Lung Specialists Society) [10], which included three
stages:
• Stage I—Moderate COPD, characterized by
moderate airﬂow limitation (FEV1/FVC <70%
but 80% >FEV1 >50% predicted);
• Stage II—Moderately severe COPD, character-
ized by worsening airﬂow limitation (50%
≥FEV1 >35% predicted);
• Stage III—Severe COPD, characterized by
severe airﬂow limitation (FEV1 ≤ 35%
predicted).
Data collected were coded and computerized
using SAS 8.0 version (2000, SAS Institute Inc.,
Cary, NC). Because the SCOPE investigators sam-
ple was stratiﬁed between GPs and lung specialists,
we adjusted the whole COPD patients sample by
using weighting factors distinguishing three sub-
groups of patients: those followed by GPs exclu-
sively (A), those followed by lung specialists
exclusively (B), and those followed in parallel
by both types of practitioners (C). The total
(A + B + C) represents the number of prevalent
treated COPD patients in France. We assumed that
the SCOPE sample of patients included by GPs and
by specialists provided unbiased estimations of the
ratios A/C and B/C, respectively. Based on these
estimations and the total prevalence, the propor-
tions of patients in the three subgroups could then
be estimated.
A descriptive and comparative analysis was car-
ried out distinguishing patients according to sever-
ity stages. A two-sided chi-square test was used for
qualitative variables and nonparametric tests (Wil-
coxon) for quantitative variables. Considering the
non-normal distribution of costs, we transformed
them with a logarithmic function and performed
ANOVA for comparison.
Secondarily, multivariate regression analyses
were used to explore the relationships between costs
associated to COPD and four parameters: FEV1
level, age, sex, and type of practitioners involved in
patients follow-up.
Results
The investigators comprised 73 GPs and 41 lung
specialists. Among the population of 327 patients
initially enrolled and fulﬁlling inclusion criteria,
only 255 had a complete follow-up and spirometric
data at the end of the study. The population ana-
lyzed was restricted to this last group (Table 1).
Characteristics of  Patients
Overall, 56% of patients had moderate COPD
(80% >FEV1 >50% predicted), 27% moderately
severe COPD (50% ≥FEV1 >35% predicted), and
17% severe COPD (FEV1 ≤ 35% predicted). The
mean age was 67 (± 21) years.
Most patients were men (81.7%) and had a
smoking history of an average of 40 pack-years.
The percentage of men was higher in severe or mod-
erately severe COPD than in moderate COPD.
More than 30% of COPD patients were still smok-
ers (23% for severe COPD and 33% for moderate
COPD). Seventy-seven percent of patients experi-
enced at least one acute exacerbation during the
year before inclusion with an average yearly
number of 1.7 episodes (SD 3.0; median 1.0).
Ninety-four percent of patients with severe COPD
had at least one exacerbation per year versus 76.3%
of patients with moderate COPD (Table 2).
Medical Resource Consumption of  COPD Patients
Patients with moderate COPD had the lowest level
of total medical resource consumption (€3,697 per
patient per year, SD €8,711, median €1,948),
whereas patients with severe COPD had the highest
one (€7,502, SD €14,575, median €3,613), and
patients with moderately severe COPD patients had
an intermediate level (€3,813, SD €9,281, median
€2,064). Costs directly associated with COPD and
its complications including exacerbations were
€1,904 (SD 6,013€, median €1,007) per patient per
year for patients with moderate COPD, €2,683 (SD
€8,516, median €1,178) for moderately severe
COPD, and €6,357 (SD €14,252, median €2,502)
for severe COPD (Tables 3 and 4).
Overall, the main cost drivers were inpatient care
(35%) and prescription medications (31%). This
was also true for COPD-associated costs, with hos-
pitalization costs representing 36% of total direct
medical costs and drugs 24% (Table 4). Respiratory
assistance and rehabilitation were also two impor-
tant costs drivers, representing 17 and 14%, respec-
tively, of the COPD associated costs.
Table 1 Study sample by type of  practitioner
Lung 
specialists GPs Total
Number of  investigators 41 73 114
Number of  enrolled patients
respecting inclusion criteria
163 164 327
Incomplete follow-up or
spirometry missing data
24 48 72
Number of  patients enrolled
in the ﬁnal analysis
139 116 255
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The distribution of costs between those associ-
ated with usual COPD follow-up, COPD complica-
tions, exacerbations, and costs related to other
comorbidities varied according to COPD severity
(Fig. 1). Exacerbations represented a higher per-
centage of costs for severe patients. Resource con-
sumption for comorbidities not related to COPD
constituted a lower proportion of total medical con-
sumption in severe COPD patients.
A linear regression analysis of the relationship
between costs associated with COPD (usual follow-
up, complications, and exacerbations) and FEV1
level conﬁrmed that patients with the most severe
COPD had the highest consumption (P < .001)
(Fig. 2). Nevertheless, the coefﬁcient of determina-
tion (R2) was low. Therefore, only the FEV1 level
could explain a small part of the variance of costs.
Similar results were observed excluding patients
who were outliers, that is, patients with costs above
the 90th percentile or considering separately
patients enrolled by GPs or lung specialists. A com-
plementary multivariate analysis using a general lin-
Table 2 Characteristics of  the COPD population in France
Weighted results
Moderate
COPD
Moderately
severe COPD
Severe
COPD Total P value
Sample size (%) 56 27 17 100
Mean age (years) 66.1 69.6 66.5 67.1 NS†
% Men 77.3 87.7 86.6 81.7 < .001*
% Former tobacco use 63.6 75.4 76.8 68.8 < .001*
Average lifetime tobacco
consumption (pack-years)
38.5 40.7 43.0 39.9 NS†
Average number of  exacerbations
per year (median)
1.7 (1) 1.5 (1) 2.0 (2) 1.7 (1) NS†
*Global chi-square between groups
†ANOVA.
Table 3 Total average annual direct medical resources consumption of  COPD patients by severity stages per patient (in €)
Weighted results
Moderate
COPD
Moderately
severe
COPD
Severe 
COPD Total (%) P value*
Drugs 1303 1394 1377 1341 (31) NS
Physician visits 177 207 220 193 (4)  .028
Diagnostic tests 132 156 138 140 (3)  .0116
Physiotherapy, Nursing 146 179 304 182 (4) < .001
Respiratory assistance 213 573 1072 455 (10) < .001
Hospitalizations 1239 958 3314 1510 (35) < .001
Rehabilitation center 458 302 957 499 (11) NS
Transportation 27 42 120 47 (1) < .001
Total direct cost (€) 3697 3813 7502 4366 (100) < .001
Median 1948 2064 3613 2203
*ANOVA using a logarithmic scale.
Table 4 Total average annual direct cost of  COPD and its complications per patient excluding medical consumption owing to
other diseases by severity stages (in €)
Weighted results
Moderate
COPD
Moderately
severe
COPD
Severe 
COPD Total P value*
Drugs 558 762 751 646 (24)  .0016
Physician visits 85 138 165 113 (4) < .001
Diagnostic tests 76 110 110 91 (3)  .0031
Physiotherapy, nursing 133 162 292 167 (6)  .0072
Respiratory assistance 213 573 1072 455 (17) < .001
Hospitalizations 548 628 2928 969 (36) < .001
Rehabilitation center 277 273 957 390 (14)  .0446
Transportation 14 38 82 32 (1) < .001
Total direct cost (€) 1904 2683 6357 2863 (100)  .001
Median 1007 1178 2502 1186
*ANOVA using a logarithmic scale.
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Figure 2 Relation between COPD-associated costs (€) and FEV1
level.
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Figure 1 Distribution of  total direct medical resources consumption
among COPD patients according to the disease grading. (Top left)
Moderate COPD; (top right) moderately severe COPD; (bottom)
severe COPD.
Follow-up
50%
Non related to
COPD
15%
Complication
8%
Exacerbation
27%
Follow-up
31%
Non related to
COPD
48%
Exacerbation
14%
Complication
7%
Follow-up
52%
Exacerbation
17%
Non related to
COPD
29%
Complication
2%
ear model showed a stronger signiﬁcant relationship
between costs associated with COPD and the cate-
gory of physician involved in the follow-up of
patients (P < .001; costs were much higher for
patients enrolled by lung specialists) than with FEV1
level (P < .001) and no signiﬁcant relationship
between those costs and age (P = .1099) or sex
(P = .7823) (Table 5).
Extrapolated to all treated COPD patients in
France, the total medical consumption of COPD
patients was €3.5 billion (€2.2 billion for COPD
and associated complications) and accounts for
3.5% of the total medical expenditures in France
(the prevalence of COPD in France was usually esti-
mated at 1.3% in the general population [11,12]).
Discussion
The SCOPE study was a ﬁrst attempt in France to
estimate the total direct medical resources con-
sumption of COPD patients according to severity.
In 1993, the annual economic burden of COPD in
the United States was estimated at $23.9 billion
[13], including $14.7 billion in direct expenditures
for medical care services. With an estimated preva-
lence rate of COPD of 61.9 in 1,000 individuals, in
the United States [14], the estimated direct cost of
COPD was $1,522 per COPD patient per year with
70% of costs related to hospitalizations. In 1992,
Medicare annual per capita expenditures for people
with COPD ($8482) were nearly 2.5 times higher
than annual expenditures for people without COPD
($3511) [15]. In 2000, Medicare expenditures in the
United States were US$11,841 for patients with
COPD compared with US$4,901 for all covered
patients [16].
In Sweden, the direct cost of COPD-related med-
ical care was estimated at 1.085 billion SEK (about
US$179.4 million) in 1991, i.e., roughly 1% of the
economic cost of all diseases combined [17].
In 1996, the direct cost of COPD in UK was
approximately £846 million (US$1.393 billion) or
£1154 (US$1900) per patient per year [18]. Phar-
maceutical expenditures for COPD and allied
conditions accounted for 11.0% of the total expen-
ditures for prescription medications.
In 1993, the direct cost of COPD in the Nether-
lands was estimated to exceed US$256 million or
US$813 per patient per year [19]. Inpatient care
accounted for 57% of the total direct cost of
COPD, and medications accounted for an addi-
tional 23%.
The SCOPE study was designed as much as pos-
sible to minimize biased estimates and produce rep-
resentative results. The protocol required a random
selection of practitioners, the systematic enrollment
of all consecutive patients meeting inclusion crite-
ria, and the exclusion of patients without conﬁrmed
spirometry.
Characteristics of patients were similar to previ-
ously published results with regard to the distribu-
tion of patients among COPD stages and frequency
Table 5 Multiple regression analysis using a general linear
model where a logarithmic transformation of  the total average
annual direct cost of  COPD is the dependent variable
Variable Coefﬁcient P value
Age 0.03 .11
Sex (female vs. male) -0.06 .78
FEV1 -0.02 <.0001
Patients follow-up (patients followed by
GPs only vs. patients followed by lung 
specialists)
-1.6 <.0001
Intercept 8.06 <.0001
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of exacerbations. In a sample of 413 patients with
COPD, Hilleman et al. [20] found a proportion of
50% of moderate COPD, 28% of moderately
severe COPD, and 22% of severe COPD. Approx-
imately 47% of patients had a single exacerbation
over 24 months, and 25% had between three and
seven episodes. Those ﬁgures are consistent with the
Euroscope study results [21]. Frequency of exacer-
bations was associated with both severity of symp-
toms and reduction of FEV1.
The SCOPE study conﬁrmed also other previous
results [20], which have shown total treatment costs
to be highly correlated with disease severity. In
addition, our results suggested that the medical con-
sumption of patients with COPD increased signiﬁ-
cantly only beyond a threshold of severity. The total
costs appeared not to increase substantially for
patients with moderately severe COPD compared
with moderate COPD (P = .4829). In contrast,
patients with severe COPD had threefold higher
costs compared with patients with less severe
COPD. These results were less convincing consider-
ing only the costs associated with COPD and its
complications. The gap between costs associated to
moderate COPD and moderately severe COPD is
less important compared with the one between costs
associated to moderately severe COPD and severe
COPD, but statistically signiﬁcant (P = .0307).
We based our analysis on the diagnosis and stag-
ing recommendations of the French Pneumological
Society [10], which use FEV1 cut-points that are
slightly different from those of the GOLD group;
that is, we did not include COPD patients with a
normal lung function.
In this study, as in most previous ones, hospital-
ization was the most important cost driver at all
stages of COPD severity. Inpatient care represented
36% of COPD costs in our study versus 39% in
data provided by Friedman and Hilleman [22] for
the United States about 10 years ago. Cost of drugs
accounted for 24% in SCOPE versus 16% in the
same study. Respiratory assistance, that is, oxygen
therapy, and rehabilitation also contributed for a
signiﬁcant part of the total COPD costs.
Nevertheless, the SCOPE study had some limita-
tions owing to the relatively small sample size and
possible recall bias owing to its partly retrospective
design. Results of the SCOPE study might also
underestimate the true direct medical resources con-
sumption of COPD patients owing to the strict
inclusion criteria used and to the fact that only out-
patients were included.
In addition, the SCOPE study did not consider
indirect costs of COPD. Such costs reﬂect the mon-
etary consequences of disability, days off work,
caregiver assistance, etc., related to the illness that
are often difﬁcult to valuate. Several international
studies have highlighted the importance of indirect
costs in COPD but results vary considerably among
them. In the SCOPE study, among the 36% of active
patients, more than 50% had a sick leave of at least
1 day during a 3-month period.
Conclusion
Previous studies have consistently found that COPD
represents a substantial economic and social burden
worldwide. The SCOPE study revealed the high
level of consumption of medical resources by
patients with COPD in France. The burden of
COPD itself and of its complications is considerable
especially for severe COPD. Nevertheless, there
were few differences between patients with moder-
ate and moderately severe COPD according to the
French Lung Specialists Classiﬁcation.
This study was supported by an unrestricted grant from
GlaxoSmithKline.
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